The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists
(VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important …

New oral anticoagulants (OACs) that directly inhibit Factor Xa (FXa) or thrombin have been
developed for the long-term prevention of thromboembolic disorders. These novel agents …

Vitamin K antagonists have been in wide use for over 70 years. Warfarin, the most
commonly used vitamin K antagonist, has been shown to be highly effective in treating and …

Background: apixaban (BMS-562247)(Eliquis®) is a novel, orally active, selective, direct,
reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was …

Purpose The involvement of the intestinally expressed xenobiotic transporters P-
glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in …

Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free
factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable …

Apixaban (Eliquis™) is an orally active and selective direct inhibitor of factor Xa indicated for
twice-daily use in the EU for the prevention of venous thromboembolism (VTE) in adults who …

Decades after the introduction of oral anti-coagulants namely the vitamin K antagonist (VKA)
Warfarin and antiplatelet agents such as Aspirin and Plavix, new classes of direct, small …

La anticoagulación oral con fármacos anti-vitamina K presenta limitaciones tales como
variabilidad en la respuesta, necesidad de controles frecuentes y tener numerosas …

Introduction Venous thromboembolism (VTE) is a common complication in patients
hospitalized for acute medical illnesses. Therefore, medical inpatients require a careful VTE …